French reimbursement for medical devices runs through the LPPR — the Liste des Produits et Prestations Remboursables — and most devices that seek individual listing go through an evaluation by CNEDIMTS, a specialist commission of the Haute Autorité de Santé. A CE mark is a prerequisite, not a reimbursement decision. The LPPR listing and the CNEDIMTS opinion are separate processes with their own evidence bar.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • LPPR is the French national list of reimbursable medical devices and services. Inclusion on LPPR is what makes a device reimbursable under the French statutory health insurance system.
  • CNEDIMTS — the Commission Nationale d'Evaluation des Dispositifs Médicaux et des Technologies de Santé — is the HAS commission that evaluates devices for LPPR listing through individual name-based inclusion.
  • The CE mark under MDR is a prerequisite. CNEDIMTS does not re-run the conformity assessment but asks different questions about clinical benefit, comparative effectiveness, and place in the treatment strategy.
  • The CNEDIMTS evaluation produces two scores that drive the decision: the Service Attendu or Service Rendu (SA / SR), which is a yes-or-no benefit judgement, and the Amélioration du Service Attendu or Rendu (ASA / ASR), which is a comparative added-value judgement against existing alternatives.
  • Timelines from dossier submission to LPPR publication commonly run 12 to 18 months, and the most common rejection reasons are insufficient comparative data and a poorly defined place in the treatment pathway.

Why this matters

France is one of the three largest medical device markets in Europe, and for many categories of device it is the market where structured national reimbursement is most clearly defined. If a startup is planning a European launch sequence that includes France, the LPPR and CNEDIMTS processes are not optional background knowledge. They are the gate between CE mark and French revenue.

The founders who learn this late discover a familiar pattern. The CE mark issues. The French sales conversations begin. The hospital or the prescriber likes the device. And then the reimbursement question surfaces and the deal stalls, because without an LPPR code the device is not systematically reimbursed and the buyer cannot justify the purchase through the usual channels.

Understanding the French pathway early — ideally before the pivotal clinical data is collected — is one of the highest-leverage planning moves a European MedTech startup can make.

What the French framework actually says

The French statutory health insurance system reimburses medical devices that appear on the LPPR. There are two main LPPR routes: inclusion under a generic description line (ligne générique), where devices that match a pre-defined technical description can be reimbursed without individual evaluation, and individual name-based inclusion (nom de marque), where the manufacturer submits a dossier and the device is evaluated on its own merits. Class IIb and III devices, and most innovative devices, typically go through the individual name-based route.

For the individual route, the manufacturer submits a dossier to HAS, and CNEDIMTS evaluates the dossier and issues an opinion. The opinion addresses two questions. First, does the device provide a Service Attendu (expected benefit) or Service Rendu (rendered benefit, for renewals)? This is a binary sufficient-or-insufficient judgement based on clinical benefit, severity of the condition, public health interest, and place in the therapeutic strategy. Second, if the benefit is sufficient, what is the Amélioration du Service Attendu or Rendu (added benefit) compared to existing alternatives?

The CNEDIMTS opinion then informs a decision by the Comité Économique des Produits de Santé (CEPS) on the price and the conditions of reimbursement, and the Ministry publishes the LPPR inclusion.

In plain language: CE mark gets the device legal in France, CNEDIMTS decides whether the French public payer thinks the device is clinically worth paying for, CEPS decides what the payer is willing to pay, and LPPR publication is the moment the reimbursement actually becomes operative. All four steps have to happen.

A worked example

A Class IIb implantable startup has a CE mark under MDR and wants to launch in France. The clinical evaluation report under MDR Article 61 and Annex XIV was built around a single-arm pivotal investigation showing safety and performance against pre-specified endpoints.

The founders meet with a French market access advisor. The advisor asks two questions. First, against which existing alternative do you want to claim added benefit? Second, what is the comparative clinical data supporting that claim?

The answers reveal a gap. The pivotal investigation had no comparator arm. It satisfied the notified body because single-arm evidence was justified given the device category and the feasibility of a randomised design. But CNEDIMTS will ask the comparative question. Without comparative data, the most likely ASA outcome is "absence of clinical added benefit" — ASA V in the traditional scale — which means listing is possible but pricing is constrained.

The founders have three options. Accept the likely ASA V and negotiate a modest price. Run a comparative post-market study as part of post-market clinical follow-up under MDR Annex XIV Part B, and resubmit in two to three years with comparative data to seek a higher ASA rating. Or generate indirect comparative evidence from matched cohorts in a real-world data source and submit that alongside the existing pivotal data.

Each option has cost and calendar implications. The point of the worked example is not that one option is correct. The point is that the choice should have been made before the pivotal investigation, not after. A comparator arm in the original study would have served both the CE mark and the CNEDIMTS submission.

The Subtract to Ship playbook

Read the HAS dossier guidance before you finalise the clinical investigation plan. The HAS guidance for medical device evaluation is publicly available and tells you exactly what CNEDIMTS expects in terms of comparator, endpoints, patient population, and place in the treatment strategy. Reading it before the study design is locked is the single highest-leverage action you can take for French reimbursement.

Define "place in the treatment strategy" as a strategic decision, not a marketing sentence. CNEDIMTS wants to know where in the patient pathway your device sits, which patient subgroup benefits, and what the alternatives for that subgroup are today. Vague positioning gets a weak opinion. Precise positioning with aligned evidence gets a strong opinion.

Pick your comparator deliberately. The comparator in your evidence should be what CNEDIMTS thinks the current standard of care is — not what you wish it was, and not what is most favourable to your device. If you pick the wrong comparator, you either lose credibility or you win a battle the commission does not care about.

Plan for twelve to eighteen months from dossier to LPPR publication. The dossier review itself, the negotiation with CEPS on price, and the publication of the inclusion are all sequential steps. Building a financial model that assumes French revenue three months after CE mark is a category error.

Use the LPPR generic line route where it is available. For some device categories, a generic description line already exists and a device matching the description can be reimbursed without going through CNEDIMTS. Check this before assuming you need a full individual evaluation.

Hire a French market access advisor before the pivotal study, not after. A French market access specialist who has done CNEDIMTS dossiers will review your clinical plan and tell you which of your design choices will cost you an ASA level. This is one of the few advisory investments that pays for itself in a measurable way.

Reality Check

  1. Have you read the current HAS methodological guidance for medical device evaluation, in full, and does your clinical plan reflect what it asks for?
  2. Is your comparator the actual current standard of care in France for your target indication, or is it a comparator chosen for a different reason?
  3. Do you have a written, specific statement of where your device sits in the French treatment pathway, and does it hold up against the HAS framing?
  4. Is there a generic LPPR line that could cover your device without an individual CNEDIMTS evaluation, and have you checked it?
  5. Does your financial model allow twelve to eighteen months from CE mark to first LPPR-reimbursed sale in France?
  6. Have you engaged a French market access advisor before locking your pivotal study design?
  7. If CNEDIMTS rates your device as providing no added clinical benefit versus the comparator, do you have a plan for that scenario, including whether to list anyway, to resubmit later, or to sequence France after other markets?

Frequently Asked Questions

Is CE mark enough to sell in France? CE mark is the legal prerequisite to place the device on the market. Selling the device into public hospitals and getting it reimbursed under statutory insurance requires LPPR listing, which for most individual devices means going through CNEDIMTS and CEPS.

What is the difference between SA and SR, and ASA and ASR? SA and ASA refer to expected benefit and expected added benefit for first evaluations. SR and ASR refer to rendered benefit and rendered added benefit for renewal evaluations after the device has been on the market.

How long does a CNEDIMTS evaluation take? From dossier submission to published opinion is commonly six to twelve months, and from opinion to actual LPPR publication after CEPS price negotiation adds several more months. Twelve to eighteen months end-to-end is a realistic planning assumption.

What are the most common reasons CNEDIMTS gives a weak opinion? Insufficient comparative data against the relevant current standard of care, a vague or unconvincing definition of the device's place in the treatment strategy, endpoints that do not match what the commission considers clinically meaningful, and a study population that does not match the intended indication.

Can I submit a CNEDIMTS dossier while the CE mark is still in progress? The CE mark is normally a prerequisite for the CNEDIMTS evaluation to lead to an LPPR listing, so the CE mark has to be in hand before the listing takes effect. Preparatory engagement with HAS can begin earlier.

Is there a fast-track pathway in France comparable to the German DiGA? France has introduced specific pathways for digital health and innovative devices over recent years, including a forfait innovation mechanism for early coverage of innovative devices under conditions.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 61 (Clinical evaluation), Annex XIV Part A and Part B.
  2. Haute Autorité de Santé (HAS) — Methodological guidance for the submission of a medical device for evaluation by CNEDIMTS.
  3. EN ISO 14155:2020+A11:2024 — Clinical investigation of medical devices for human subjects — Good clinical practice.